EGRX News and Press, Eagle Pharmaceuticals Inc. From 06/17/21

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has responded to the Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin received from the...

Eagle Pharmaceuticals has felt the impact of COVID-19, and the earnings reports have reflected that. As a result, the share price has taken a beating over the past year. The company expects to see its earnings improve over the remainder of 2021 as the country begins to reopen and pati...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: ...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference as follow...

Eagle Pharmaceuticals, Inc. (EGRX) Q1 2021 Earnings Conference Call May 10, 2021, 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Tim Lugo - William Blair Daniel Busby ...

Image source: The Motley Fool. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Q1 2021 Earnings Call May 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals Inc (EGRX) Q1 2021 Earnings Call Transcript...

Eagle Pharmaceuticals (EGRX): Q1 Non-GAAP EPS of $0.24 misses by $0.49; GAAP EPS of -$0.03 misses by $0.23.Revenue of $41.25M (-10.4% Y/Y) misses by $3.78M.2021 Expense GuidanceR&D spend in 2021, on a non-GAAP basis, is expected to be $26-$30 million, as compared to $27.8 million in 2020....

Q1 2021 net loss was $0.03 per basic and diluted share and adjusted non-GAAP net income was $0.24 per basic and diluted share Anticipate vasopressin approval and launch this year; completed last required study; expect to respond to vasopressin Complete Response Letter (“CRL&#...

- Eagle expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations - Eagle Pharmaceuticals, Inc. (“Eagle” or the &...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regul...